Cargando…

Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Shufang, Wen, Xin, Han, Fei, Long, Yin, Xu, Gaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687695/ https://www.ncbi.nlm.nih.gov/pubmed/29179525 http://dx.doi.org/10.18632/oncotarget.19382

Ejemplares similares

Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
por: Fu, Shufang, et al.
Publicado: (2018)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
por: Sureshkumar, Kalathil K
Publicado: (2008)

Aliskiren and valsartan combination therapy for the management of hypertension
por: Epstein, Benjamin J
Publicado: (2010)

Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials
por: Liu, Yukai, et al.
Publicado: (2013)

Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats
por: Pechanova, Olga, et al.
Publicado: (2019)

Efficacy of Aliskiren/Hydrochlorothiazide Combination for the Treatment of Hypertension: A Meta-Analytical Approach
por: Morgado, Manuel P, et al.
Publicado: (2011)

The optimal time of initiation of renal replacement therapy in acute kidney injury: A meta-analysis
por: Luo, Kaiping, et al.
Publicado: (2017)

Aliskiren in hypertension: evidence for its potential therapeutic value
por: Peter, Doris
Publicado: (2005)

Correction: The optimal time of initiation of renal replacement therapy in acute kidney injury: A meta-analysis
por: Luo, Kaiping, et al.
Publicado: (2018)

Can Aliskiren be Considered as a New Novel Drug for Hypertension?
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials
por: Liu, Hongzhi, et al.
Publicado: (2017)

Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials
por: Zhang, Jing-Tao, et al.
Publicado: (2015)

Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination
por: Hovater, Michael B, et al.
Publicado: (2013)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients
por: Zheng, Sean L, et al.
Publicado: (2017)

Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review
por: Shen, Jiantong, et al.
Publicado: (2021)

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
por: McMurray, John J.V., et al.
Publicado: (2012)

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
por: Pimenta, Eduardo, et al.
Publicado: (2009)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
por: Andersen, Karl
Publicado: (2009)

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
por: Pimenta, Eduardo, et al.
Publicado: (2009)

Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill
por: Burnier, Michel
Publicado: (2010)

Successful Treatment of Hypertension in Anuric Hemodialysis Patients with a Direct Renin Inhibitor, Aliskiren
por: Maeda, Yoshitaka, et al.
Publicado: (2011)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008)

Aliskiren: An orally active renin inhibitor
por: Wal, Pranay, et al.
Publicado: (2011)

Aliskiren and the dual complement inhibition concept
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Direct Renin Inhibition: Focus on Aliskiren
por: Pool, James L.
Publicado: (2007)

Aliskiren-attenuated myocardium apoptosis via regulation of autophagy and connexin-43 in aged spontaneously hypertensive rats
por: Zhang, Wenbin, et al.
Publicado: (2014)

Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews
por: Zhao, Qiyuan, et al.
Publicado: (2020)

Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension
por: Allikmets, Kristina
Publicado: (2007)

Role of aliskiren in blood pressure control and renoprotection
por: Trimarchi, Hernán
Publicado: (2011)

Renin Inhibition with Aliskiren: A Decade of Clinical Experience
por: Pantzaris, Nikolaos-Dimitrios, et al.
Publicado: (2017)

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
por: Persson, Frederik, et al.
Publicado: (2009)

First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination
por: Savvatis, Konstantinos, et al.
Publicado: (2010)

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis
por: Harel, Ziv, et al.
Publicado: (2012)

Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
por: Seki, Yasufumi, et al.
Publicado: (2023)

Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome
por: Ramalho, F. N., et al.
Publicado: (2017)

The Potential Effects of Aliskiren on Atrial Remodeling Induced by Chronic Intermittent Hypoxia in Rats
por: Miao, Shuai, et al.
Publicado: (2020)

Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways
por: Zhao, Zhengbo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vgk225uumvrpm7ji6u1vht3e43